Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03757325 | Study to Evaluate DNL747 in Subjects With Alzheimer's Disease | PHASE1 | COMPLETED | 16 | — | — | Feb 13, 2019 | Dec 5, 2019 | Feb 26, 2020 | 5 | United States, Netherlands |
| Arm | Type | Description |
|---|---|---|
| DNL747 First, Placebo Second | EXPERIMENTAL | Subjects will receive DNL747 for 29 days for the first period and then will switch to placebo for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods. |
| Placebo First, DNL747 Second | EXPERIMENTAL | Subjects will receive placebo for 29 days for the first period and then will switch to DNL747 for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods. |
| Name | Type | Description |
|---|---|---|
| DNL747 | DRUG | DNL747 |
| Placebo | DRUG | Placebo |
Key Inclusion Criteria: * Women of non-childbearing potential and men, aged 55-85 years * AD diagnosis based on the 2011 National Institute on Aging-Alzheimer's Association Guidelines * Supportive evidence for diagnosis of AD based upon positive CSF Aβ42 test, or documented history of positive amyl...